SSTR2 and prostate carcinoma: In addition, the chromatin modulators, including demethylating agents and HDAC inhibitors, were reported to upregulate SSTR2 expression and thus increased tumor uptake of the radiolabeled octreotide in neuroendocrine and prostate cancer cells (23).